0.25 mg of semaglutide Ozempic® Pen Dosing Semasize 0.25mg/0.5 Injection (1 Multi-dose

Marketed as Wegovy, the glucagon-like peptide-1 (GLP-1) receptor agonist will be available in specialist NHS weight management services for people who meet the []

Why This Matters for Clinical & Commercial Strategy: The collaboration signals: Increasing competition in the GLP-1 segment Strategic brand differentiation in high-demand therapies Strong focus on access expansion beyond metro & premium clinics Growing India focus in metabolic & obesity management For professionals in Clinical Research, Market Access, and Business Development, this is a clear indicator of how partnerships are shaping the next phase of diabetes and obesity care in India

From Facebook ads to YouTube testimonials, AAFQ - & are being pushed as a miraculous health solution.

Additionally, if CV risk was managed upstream through weight reduction, unmet need due to high residual CV risk would likely manifest itself in specific patient sub-segments and thus require innovators to take a highly targeted approach in both clinical development and commercialisation

Mounjaro and Ozempic both help control blood sugar and promote weight loss in people with diabetes